Ovid Therapeutics (OVID) Stock Forecast, Price Target & Predictions
OVID Stock Forecast
Ovid Therapeutics stock forecast is as follows: an average price target of $7.33 (represents a 521.19% upside from OVID’s last price of $1.18) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
OVID Price Target
The average price target for Ovid Therapeutics (OVID) is $7.33 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $3.00. This represents a potential 521.19% upside from OVID's last price of $1.18.
OVID Analyst Ratings
According to 5 Wall Street analysts, Ovid Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for OVID stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Ovid Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 02, 2024 | Raghuram Selvaraju | H.C. Wainwright | $3.00 | $0.86 | 247.95% | 154.24% |
| May 20, 2024 | Thomas Shrader | BTIG | $11.00 | $3.14 | 250.32% | 832.20% |
| May 14, 2024 | Francois Brisebois | Oppenheimer | $8.00 | $3.23 | 147.68% | 577.97% |
The latest Ovid Therapeutics stock forecast, released on Jul 02, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $3.00, which represents a 247.95% increase from the stock price at the time of the forecast ($0.86), and a 154.24% increase from OVID last price ($1.18).
Ovid Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $7.33 |
| Last Closing Price | $1.18 | $1.18 | $1.18 |
| Upside/Downside | -100.00% | -100.00% | 521.19% |
In the current month, the average price target of Ovid Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Ovid Therapeutics's last price of $1.18. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 19, 2024 | Citigroup | Underperform | Underperform | Hold |
| Aug 19, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 26, 2024 | Citigroup | Underperform | Underperform | Hold |
| Jul 26, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 18, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jun 18, 2024 | B. Riley | Buy | Buy | Hold |
| Jun 18, 2024 | Wedbush | Buy | Buy | Hold |
| Jun 18, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jun 18, 2024 | Oppenheimer | Outperform | Perform | Downgrade |
| Jun 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Ovid Therapeutics's last stock rating was published by Citigroup on Aug 19, 2024. The company gave OVID a "Underperform" rating, the same as its previous rate.
Ovid Therapeutics Financial Forecast
Ovid Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $108.97M | $75.00M | $66.16K | $1.45M | $208.38M | $5.70M | $6.91M |
| Avg Forecast | $106.33K | $114.67K | $8.82M | $131.33K | $108.63K | $105.50K | $65.38K | $52.08K | $8.62M | $45.83K | $47.75K | $18.77K | $1.31M | $100.53M | $4.16M | $100.00K |
| High Forecast | $106.33K | $114.67K | $8.82M | $131.33K | $108.63K | $133.63K | $65.56K | $52.08K | $11.20M | $45.83K | $47.75K | $18.77K | $1.57M | $100.53M | $4.16M | $100.00K |
| Low Forecast | $106.33K | $114.67K | $8.82M | $131.33K | $108.63K | $70.33K | $65.19K | $52.08K | $6.89M | $45.83K | $47.75K | $18.77K | $1.05M | $100.53M | $4.16M | $100.00K |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 8 | 4 | 5 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | 2377.59% | 1570.68% | 3.53% | 1.11% | 2.07% | 1.37% | 69.14% |
Ovid Therapeutics's average Quarter revenue forecast for Dec 23 based on 4 analysts is $8.62M, with a low forecast of $6.89M, and a high forecast of $11.20M. OVID's average Quarter revenue forecast represents a -92.09% decrease compared to the company's last Quarter revenue of $108.97M (Sep 23).
Ovid Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 8 | 4 | 5 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-12.03B | $-14.17B | $-14.89M | $-16.19M | $176.58M | $-21.95M | $-16.35M |
| Avg Forecast | $-29.83K | $-32.17K | $-2.48M | $-36.85K | $-30.48K | $-29.60K | $-18.34K | $-14.61K | $-2.42M | $-12.86K | $-13.40K | $-5.26K | $-14.46M | $95.96M | $-1.17M | $-28.05K |
| High Forecast | $-29.83K | $-32.17K | $-2.48M | $-36.85K | $-30.48K | $-19.73K | $-18.29K | $-14.61K | $-1.93M | $-12.86K | $-13.40K | $-5.26K | $-11.57M | $115.16M | $-1.17M | $-28.05K |
| Low Forecast | $-29.83K | $-32.17K | $-2.48M | $-36.85K | $-30.48K | $-37.49K | $-18.39K | $-14.61K | $-3.14M | $-12.86K | $-13.40K | $-5.26K | $-17.35M | $76.77M | $-1.17M | $-28.05K |
| Surprise % | - | - | - | - | - | - | - | - | - | 935513.45% | 1057926.40% | 2828.55% | 1.12% | 1.84% | 18.78% | 582.64% |
8 analysts predict OVID's average Quarter EBITDA for Mar 22 to be $-14.46M, with a high of $-11.57M and a low of $-17.35M. This is -108.19% lower than Ovid Therapeutics's previous annual EBITDA (Mar 21) of $176.58M.
Ovid Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 8 | 4 | 5 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | $-11.25B | $-12.41B | $1.52B | $-16.11M | $176.01M | $-22.03M | $-16.42M |
| Avg Forecast | $-13.42M | $-13.23M | $-6.50M | $-12.67M | $-13.45M | $-14.65M | $-15.88M | $-15.85M | $-3.58M | $-13.15M | $-14.49M | $-12.14M | $-14.57M | $95.65M | $-21.67M | $-24.85M |
| High Forecast | $-13.42M | $-13.23M | $-6.50M | $-12.67M | $-13.45M | $-11.56M | $-15.88M | $-15.85M | $-3.37M | $-13.15M | $-14.49M | $-12.14M | $-11.66M | $114.78M | $-21.67M | $-24.85M |
| Low Forecast | $-13.42M | $-13.23M | $-6.50M | $-12.67M | $-13.45M | $-18.50M | $-15.88M | $-15.85M | $-3.58M | $-13.15M | $-14.49M | $-12.14M | $-17.49M | $76.52M | $-21.67M | $-24.85M |
| Surprise % | - | - | - | - | - | - | - | - | - | 855.65% | 856.57% | -125.44% | 1.11% | 1.84% | 1.02% | 0.66% |
Ovid Therapeutics's average Quarter net income forecast for Jun 23 is $-14.49M, with a range of $-14.49M to $-14.49M. OVID's average Quarter net income forecast represents a -100.95% decrease compared to the company's last Quarter net income of $1.52B (Mar 23).
Ovid Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 8 | 4 | 5 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | $6.81B | $8.25B | $8.34M | $9.88M | $15.58M | $10.41M | $7.44M |
| Avg Forecast | $2.16M | $2.33M | $179.19M | $2.67M | $2.21M | $2.14M | $1.33M | $1.06M | $174.97M | $930.82K | $969.75K | $381.14K | $26.56M | $8.47M | $84.57M | $2.03M |
| High Forecast | $2.16M | $2.33M | $179.19M | $2.67M | $2.21M | $2.71M | $1.33M | $1.06M | $227.46M | $930.82K | $969.75K | $381.14K | $31.87M | $10.16M | $84.57M | $2.03M |
| Low Forecast | $2.16M | $2.33M | $179.19M | $2.67M | $2.21M | $1.43M | $1.32M | $1.06M | $139.98M | $930.82K | $969.75K | $381.14K | $21.25M | $6.77M | $84.57M | $2.03M |
| Surprise % | - | - | - | - | - | - | - | - | - | 7311.02% | 8505.53% | 21.89% | 0.37% | 1.84% | 0.12% | 3.66% |
Ovid Therapeutics's average Quarter SG&A projection for Dec 23 is $174.97M, based on 4 Wall Street analysts, with a range of $139.98M to $227.46M. The forecast indicates a -97.43% fall compared to OVID last annual SG&A of $6.81B (Sep 23).
Ovid Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 8 | 4 | 5 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | $-159.34 | $-0.18 | $21.60 | $-0.23 | $2.55 | $-0.34 | $-0.28 |
| Avg Forecast | $-0.19 | $-0.19 | $-0.09 | $-0.18 | $-0.19 | $-0.21 | $-0.22 | $-0.22 | $-0.05 | $-0.19 | $-0.20 | $-0.17 | $-0.21 | $1.45 | $-0.31 | $-0.35 |
| High Forecast | $-0.19 | $-0.19 | $-0.09 | $-0.18 | $-0.19 | $-0.16 | $-0.22 | $-0.22 | $-0.05 | $-0.19 | $-0.20 | $-0.17 | $-0.21 | $1.45 | $-0.31 | $-0.35 |
| Low Forecast | $-0.19 | $-0.19 | $-0.09 | $-0.18 | $-0.19 | $-0.26 | $-0.22 | $-0.22 | $-0.05 | $-0.19 | $-0.20 | $-0.17 | $-0.21 | $1.45 | $-0.31 | $-0.35 |
| Surprise % | - | - | - | - | - | - | - | - | - | 859.25% | 0.88% | -126.18% | 1.11% | 1.76% | 1.11% | 0.80% |
According to 2 Wall Street analysts, Ovid Therapeutics's projected average Quarter EPS for Jun 23 is $-0.20, with a low estimate of $-0.20 and a high estimate of $-0.20. This represents a -100.95% decrease compared to OVID previous annual EPS of $21.60 (Mar 23).
Ovid Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $1.29 | $10.00 | 675.19% | Buy |
| OVID | Ovid Therapeutics | $1.18 | $7.33 | 521.19% | Buy |
| CTMX | CytomX Therapeutics | $1.01 | $5.77 | 471.29% | Buy |
| NUVB | Nuvation Bio | $2.29 | $6.75 | 194.76% | Buy |
| TIL | Instil Bio | $27.63 | $78.25 | 183.21% | Hold |
| NXTC | NextCure | $1.31 | $3.00 | 129.01% | Buy |
| ASMB | Assembly Biosciences | $16.98 | $35.50 | 109.07% | Buy |
| ACHL | Achilles Therapeutics | $1.03 | $2.00 | 94.17% | Buy |
| CNTB | Connect Biopharma | $1.20 | $1.50 | 25.00% | Buy |
OVID Forecast FAQ
Is Ovid Therapeutics a good buy?
Yes, according to 5 Wall Street analysts, Ovid Therapeutics (OVID) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of OVID's total ratings.
What is OVID's price target?
Ovid Therapeutics (OVID) average price target is $7.33 with a range of $3 to $11, implying a 521.19% from its last price of $1.18. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Ovid Therapeutics stock go up soon?
According to Wall Street analysts' prediction for OVID stock, the company can go up by 521.19% (from the last price of $1.18 to the average price target of $7.33), up by 832.20% based on the highest stock price target, and up by 154.24% based on the lowest stock price target.
Can Ovid Therapeutics stock reach $2?
OVID's average twelve months analyst stock price target of $7.33 supports the claim that Ovid Therapeutics can reach $2 in the near future.
What are Ovid Therapeutics's analysts' financial forecasts?
Ovid Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $331.58K (high $359.9K, low $296.22K), average EBITDA is $-93.024K (high $-83.105K, low $-101K), average net income is $-59.826M (high $-56.742M, low $-63.68M), average SG&A $6.73M (high $7.31M, low $6.02M), and average EPS is $-0.844 (high $-0.8, low $-0.898). OVID's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $9.18M (high $9.18M, low $9.18M), average EBITDA is $-2.574M (high $-2.574M, low $-2.574M), average net income is $-45.828M (high $-45.828M, low $-45.828M), average SG&A $186.34M (high $186.34M, low $186.34M), and average EPS is $-0.646 (high $-0.646, low $-0.646).
Did the OVID's actual financial results beat the analysts' financial forecasts?
Based on Ovid Therapeutics's last annual report (Dec 2023), the company's revenue was $391.7M, beating the average analysts forecast of $8.73M by 4387.84%. Apple's EBITDA was $-59.281B, beating the average prediction of $-2.449M by 2420842.10%. The company's net income was $-52.339B, beating the average estimation of $-43.355M by 120622.06%. Apple's SG&A was $31.09B, beating the average forecast of $177.25M by 17437.11%. Lastly, the company's EPS was $-0.74, beating the average prediction of $-0.611 by 21.04%. In terms of the last quarterly report (Sep 2023), Ovid Therapeutics's revenue was $108.97M, beating the average analysts' forecast of $45.83K by 237658.82%. The company's EBITDA was $-12.029B, beating the average prediction of $-12.858K by 93551245.47%. Ovid Therapeutics's net income was $-11.252B, beating the average estimation of $-13.151M by 85464.60%. The company's SG&A was $6.81B, beating the average forecast of $930.82K by 731001.85%. Lastly, the company's EPS was $-159, beating the average prediction of $-0.185 by 85825.37%